Accueil   Diary - News   All news First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

 

Strasbourg, France, September 19, 2017, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated at the Curie Institute, Paris, France, in a Phase 1b/2 clinical trial evaluating the combination of TG4001 with avelumab* as a treatment for human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers, such as oropharyngeal squamous cell carcinoma of the head and neck (SCCHN). This subtype of cancer represents more than 80% of oropharynx cancers.

 

This multi-center, open-label trial will assess the safety and tolerability, as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 50 patients (NCT03260023).

Prof. Christophe Le Tourneau, M.D., Head of the Early Phase Program at the Curie Institute, and a world expert in head and neck cancers, is the Principal Investigator of the study. 

 

 

More information on the trial is available on: clinicaltrials.gov

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree